Influence of Risk Factors on Bone Density in Inflammatory Bowel Diseases
Abstract
Background/Aim: Young people and teenagers are often affected by chronic inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Prolonged and continuous inflammation, the release of inflammatory mediators with increased osteoclastic activity and reduced osteoblast activity, lead to accelerated bone mineral loss. Glucocorticoid (GC) utilisation in the pharmacotherapy of inflammatory bowel disease (IBD) and malabsorption are additional risk factors affecting bone mineral density (BMD). The main objective of this research was to assess the influence smoking, coffee, alcohol, physical activity and therapy on BMD in chronic inflammation the digestive system.
Methods: A retrospective study included 30 respondents with IBD, average age 34.0 ± 6.73. Participants were divided according to the type of disease into the categories of Crohn disease - CD (n = 14) and ulcerative colitis - UC (n = 16). All patients had their BMD determined by osteodensitometry.
Results: Osteopenia was present in 56.7 % of patients. A statistically significantly higher percentage of patients with UC had osteopenia (40 % vs 16.7 %, p < 0.05). Osteoporosis (OP) was not recorded in the study participants. Smoking and coffee consumption were the most common risk factors. Studying risk factors showed that treatment with GC therapy led to a statistically markedly reduced BMD in form of osteopenia in respondents with UC (40 % vs CD 16.7 %, p < 0.05).
Conclusion: Presented study's findings indicated that 50 % of the patients presented with reduced BMD in the form of osteopenia, which was more present in UC patients. In this study, only the use of GC had a statistically significant negative effect on BMD.
References
Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb 1;13(2):144-164. doi: 10.1093/ecco-jcc/jjy113.
Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterol. Rev./Przegląd Gastroenterol. 2021;16:257-96. doi: 10.5114/pg.2021.110914.
Kreienbuehl AS, Rogler G, Emanuel B, Biedermann L, Meier C, Juillerat P. et al. Bone health in patients with inflammatory bowel disease. Swiss Med Wkly. 2024. 10;154:3407. doi: 10.57187/s.3407.
Mundy GR. Osteoporosis and Inflammation. Nutr Rev. 2007;65:S147-S151. doi: 10.1111/j.1753-4887.2007.tb00353.x.
Kreienbuehl AS, Rogler G, Emanuel B, Biedermann L, Meier C, Juillerat P, et al. Bone health in patients with inflammatory bowel disease. Swiss Med Wkly. 2024 Jun 10;154:3407. doi: 10.57187/s.3407.
Ratajczak AE, Szymczak-Tomczak A, Zawada A, Rychter AM, Dobrowolska A, Krela-Kaźmierczak I. Does drinking coffee and tea affect bone metabolism in patients with inflammatory bowel diseases? Nutrients. 2021;13:216. doi: 10.3390/nu13010216.
World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser 1994; 843: 1-129. PMID: 7941614.
Gupta S, Wu X, Moore T, Shen B. Frequency, risk factors, and adverse sequelae of bone loss in patients with ostomy for inflammatory bowel diseases. Infl Bowel Dis. 2014; 20(2):259–64. doi: 10.1097/01.MIB.0000439065.92211.d3.
Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13(3):259-65. doi: 10.1111/j.1756-185X.2010.01542.x.
Schule S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, et al. Widery differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD Cohort Study. Medicine. 2017; 96:e6788. doi: 10.1097/MD.0000000000006788.
Yin Y, Lu X, Li Z, Liu S, Shao L, Cao L, et al. Risk factors for worsening of bone loss in patients newly diagnosed with inflammatory bowel disease. Gastroenterol Res Pract. 2022 Apr 4;2022:1498293. doi: 10.1155/2022/1498293.
Ratajczak A, Szymczak-Tomczak A, Michalak M, Rychter AM, Zawada A, Dobrowolska A, et al. The associations between vitamin D, bone mineral density and the course of inflammatory bowel disease in Polish patients. Pol Arch Intern Med 2022;26:16329. doi: 10.20452/pamw.16329.
Azzopardi N, Ellul P. Risk factors for osteoporosis in Crohn’s disease: infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013;19:1173-8. doi: 10.1097/MIB.0b013e31828075a7.
Atreja A, Aggarwal A, Licata AA, Lashner BA. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. Sci World J. 2012;2012:807438. doi: 10.1100/2012/807438.
Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis. 2010;28:411-7. doi: 10.1159/000320395.
Lo B, Holm JP, Vester-Andersen MK, Bendtsen F, Vind I, Burisch J. Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: a Danish population-based inception cohort with 10 years of follow-up. J Crohn Colitis. 2020 Jul 30;14(7):904-14. doi: 10.1093/ecco-jcc/jjaa019.
Bergmann MM, Hernandez V, Bernigau W, Boeing H, Chan SSM, Luben R, et al. No association of alcohol use and the risk of ulcerative colitis or Crohn’s disease: data from a European Prospective Cohort Study (EPIC). Eur J Clin Nutr. 2017;71:512-8. doi: 10.1038/ejcn.2016.271.
Holik D, Včev A, Milostić-Srb A, Salinger Ž, Ivanišević Z, Včev I. et al. The effect of daily physical activity on the activity of inflammatory bowel diseases in therapy in therapy-free patients, Acta Clin Croat. 2019. Jun;58(2):202-12. doi: 10.20471/acc.2019.58.02.02
Sigurdsson, G.V, Schmidt, S, Mellström, D, Ohlsson, C, Karlsson, M, Lorentzon, M, et al. Physical exercise is associated with beneficial bone mineral density and body composition in young adults with childhood-onset inflammatory bowel disease. Scand J Gastroenterol. 2021;56:699-707. doi: 10.1080/00365521.2021.1913759.
Gravina AG, Pellegrino R, Palladino G, Imperio G, D'Onofrio R, Arboretto G. Patient-reported physical activity of IBD patients is of concern when weighed with the international physical activity questionnaire regardless of disease activity and IBD phenotype: barriers and facilitators emerged from the extended "BE-FIT-IBD" cross-sectional study. J Crohn Colitis. 2024;18(1):i1980. doi: 10.1093/ecco-jcc/jjad212.1231.
Kärnsund S, Lo B, Bendtsen F, Holm J, Burisch J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J. Gastroenterol. 2020;26:5362-74. doi: 10.3748/wjg.v26.i35.5362.
Lo B, Holm JP, Vester-Andersen M.K., Bendtsen F, Vind I, Burisch J. Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: a Danish population-based inception cohort with 10 years of follow-up. J Crohn Colitis. 2020;14(7):904–14. doi: 10.1093/ecco-jcc/jjaa019.
Targownik LE, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol. 2014 Mar;30(2):168-74. doi: 10.1097/MOG.0000000000000037.
Abraham BP, Prasad P, Malaty HM. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Dig Dis Sci. 2014 Aug;59(8):1878-84. doi: 10.1007/s10620-014-3102-x.
Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. PM R. 2011 May;3(5):466-71; quiz 471. doi: 10.1016/j.pmrj.2011.02.017.
Lima CA, Lyra AC, Mendes CMC, Lopes MB, Coqueiro FG, Rocha R, et al. Bone mineral density and inflammatory bowel disease severity. Braz J Med Biol Res. 2017; 19:50(12):e63749. doi: 10.1590/1414-431X20176374
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).